Dr. Brian Druker receives Excellence in Molecular Diagnostics Award

November 20, 2015

druker Earlier this month, Brian Druker, M.D., Director of the Knight Cancer Institute at OHSU, received a prestigious award for Excellence in Molecular Diagnostics from The Association for Molecular Pathology (AMP). "This award is the highest honor bestowed by the association," said AMP President, Janina Longtine, M.D.

The Association for Molecular Pathology is a non-profit organization providing structure, leadership and expertise in molecular diagnostics—one of the fastest growing fields in healthcare. The award recognizes Druker's work in the development and clinical trials of the drug Gleevec, used to treat chronic myeloid leukemia. Gleevec was the first of its kind; developed to fight cancer by targeting mutated cells, leaving healthy cells alone and causing only minimal side effects.

Read more